SCHEMBL6038690

SCHEMBL6038690

Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCC2CCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 7/20 0.59
KDM4E B2RXH2 7/20 0.59
HSD17B10 Q99714 2/20 0.59
LMNA P02545 2/20 0.59
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
CFTR P13569 1/20 0.54
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 1/20 0.49
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
TTR P02766 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038985 0.99 EDNRA (0.58) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038590 0.91 KDM4E (0.67) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038650 0.90 KDM4E (0.66) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038871 0.89 KDM4E (0.58) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038571 0.89 MEN1 (0.58) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6039111 0.89 KDM4E (0.60) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038595 0.89 MEN1 (0.70) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038818 0.89 MEN1 (0.66) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038981 0.88 KDM4E (0.57) EDNRAKDM4EHSD17B10LMNAMEN1
SCHEMBL6038402 0.88 KDM4E (0.57) EDNRAKDM4EHSD17B10LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 EDNRA 512/4885KDM4E 3561/4885HSD17B10 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.